The Clinical Trials Management Shared Resource (CTMSR) is led by Raymond P. Perez, MD and provides comprehensive, centralized support services that span the life cycle of cancer clinical trials from concept through manuscript, and assures that the patient population and resources needed to successfully conduct these trials in compliance with all federal, state and local regulations are in place. A resource staff of 35.6 FTE manage a portfolio of 116 clinical protocols (19 institutional investigator-initiated, 31 industrial, and 65 from cooperative groups). The CTMSR is functionally organized into four distinct groups: (1) Study Implementation and Regulatory Compliance (11 FTE) provides project development/management and regulatory affairs functions, and administrative support for the KUCC Protocol Review and Monitoring System;(2) Research Finance (2 FTE) provides comprehensive budget development, financial management for active protocols, and research billing compliance;(3) Clinical Trials (17.6 FTE) provides research nursing, study coordination, and data management coordination;and, (4) Research Assurance (1 FTE) provides monitoring, auditing, and quality assurance/control (QA/QC) oversight of clinical research and administratively supports the KUCC Data and Safety Monitoring Committee. The CTMSR has enabled a nearly 5-fold increase in clinical trials accrual at KUCC since 2006, particularly to institutional investigator-initiated trials (IIT) that now account for almost 63% of all therapeutic enrollments. Additional operational highlights include development and improvement of standard operating procedures across the resource, particularly for financial management, where process improvements yielded a sustainable business model, and support for local and regional collaborations at multiple affiliated sites. In summary, the CTMSR has facilitated significant growth of investigator-driven clinical research at KUCC, while implementing and administering cost-effective processes to ensure that the research activities have scientific merit, protect safety, maintain scientific integrity, and are fiscally sound.
Advancing cancer care, today and tomorrow will require new and better therapies based on our ever increasing understanding of cancer and anficancer drugs. These improvements will depend on careful, properiy-conducted clinical research. The Clinical Trials Management shared resource provides KUCC cancer researchers with the support and services to conduct clinical research of the highest possible quality.
|Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98|
|Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040|
|Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89|
|Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26|
|(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675|
|Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412|
|Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92|
|Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38|
|Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336|
|(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401|
Showing the most recent 10 out of 93 publications